Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter.

The Motley Fool • Dec 9, 2025

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.

Business Wire • Dec 5, 2025

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?

New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (AUM).

The Motley Fool • Dec 3, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 4, 2025

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

PRNewsWire • Nov 28, 2025

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

California-based TCG Crossover bought 300,000 shares of Amylyx Pharmaceuticals for an estimated $46.8 million in the third quarter. At quarter-end, TCG Crossover reported holding 6.2 million total shares of Amylyx shares valued at $84.9 million.

The Motley Fool • Nov 17, 2025

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.

Business Wire • Nov 13, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lindsey Allen Justin Klee - Co-Founder, Co-CEO & Director Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Marc Goodman - Leerink Partners LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Christopher Chen - Robert W. Baird & Co. Incorporated, Research Division Susan Chor Ananda Ghosh - H.C.

Seeking Alpha • Nov 6, 2025

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025. “Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “We continue to advance our lead asset avexitide, an investiga.

Business Wire • Nov 6, 2025

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences.

Business Wire • Nov 3, 2025